Type: Oral
Session: 628. Aggressive Lymphomas: Cellular Therapies: Novel Strategies for Cell Therapies in Aggressive Lymphomas
Hematology Disease Topics & Pathways:
Lymphomas, Non-Hodgkin lymphoma, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diseases, Treatment Considerations, Biological therapies, Lymphoid Malignancies
Methods: This retrospective, multicenter study utilized Center for International Blood and Marrow Transplant Research (CIBMTR) data to assess outcomes of DLBCL patients treated with commercial CD19 CAR-T therapies for treatment of r/r LBCL from 2017 and 2023. Patient-, disease-, and CAR T-related factors were compared between LD regimens using Chi-square test for categorical variables and Wilcoxon two-sample test for continuous variables. The probability of overall survival (OS) and progression-free survival (PFS) were calculated using the Kaplan-Meier estimator. The probability of overall response rate (ORR) was estimated using cumulative incidence estimates with deaths before ORR as a competing risk. A Cox proportional hazards model was used to identify the significant factors for PFS, OS, and ORR. Logistic regression models were fitted for any grade and severe (grade >3) CRS and ICANS, and prolonged cytopenia.
Results: We identified 5,256 patients with DLBCL treated with axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), or lisocabtagene maraleucel (liso-cel) during the study period. Of these, 4,809 (92.4%) received fludarabine LD and 447 (8.5%) received bendamustine LD. The median follow-up was 23.8 and 9.8 months for fludarabine and bendamustine, respectively. ORR at day 180 was 60% for all patients, with higher rates in the fludarabine group vs. bendamustine group (61.2% vs. 50.8%, p<0.01). The cumulative incidence of CR/PR at day 180 was also higher in the fludarabine group (79.1% vs. 70.2%, p<0.01). The 6- and 12-month PFS was 54.5% and 45.4% for fludarabine vs. 51.4% and 39.1% for bendamustine (p=0.04). No significant differences were observed in OS at 6 and 12 months (61% and 62.2% for fludarabine vs. 77.9% and 61.0% for bendamustine, p=0.65). Multivariate analyses indicated that bendamustine had an inferior ORR (hazard ratio [HR] 0.773, p=0.0013) but there was no difference in CR (HR 0.828, p=0.0606), PFS (HR 1.081, p=0.4990), or OS (HR 1.136, p=0.4194) compared to fludarabine. Age ≤ 65 years was associated with inferior ORR (HR 0.859, p<0.0001) and CR (HR 0.77, p<0.001) after adjusting for LD regimen. Axi-cel (HR 1.5) and liso-cel (HR 1.4) had higher ORR than tisa-cel (p<0.0001) after adjusting for LD regimen. A subset analysis during 2021-2023 adjusting for a more even distribution of LD regimens across CAR T products was performed and the main conclusions were the same.
Recipients of bendamustine experienced lower rates of severe CRS and ICANS compared to those who received the fludarabine (CRS: 4.5% vs. 7.7%, p=0.01; ICANS: 8.3% vs. 16.7%, p<0.01). Additionally, prolonged cytopenia was less common with bendamustine (11.6% vs. 20%, p<0.01). The multivariate analysis confirmed these findings, indicating that bendamustine was associated with lower CRS (odds ratio [OR] 0.445, p<0.0001), ICANS (OR 0.432, p<0.0001), and prolonged cytopenia (OR 0.479, p<0.0001) compared to fludarabine. Liso-cel was associated with lower CRS (OR 0.381, p <0.0001), ICANS (OR 0.507, p<0.0001), and prolonged cytopenia (OR 0.519, p=0.0002) compared to axi-cel and tisa-cel.
Conclusion: Patients receiving fludarabine-based LD had higher ORR, but similar CR without a significant impact on either PFS or OS compared to those receiving bendamustine across CAR T-cell products for treatment of LBCL. Bendamustine was associated with a reduced incidence of severe CRS, ICANS, and prolonged cytopenia. Relevant patient characteristics may inform the choice of LD, considering the trade-off between efficacy and safety. Bendamustine can be considered an alternative LD prior to CAR T for LBCL.
Disclosures: Ahmed: BMS: Consultancy, Honoraria; Kite/Gilead: Consultancy, Honoraria; Legend Biotech: Consultancy, Honoraria. Mirza: BMS: Speakers Bureau. Strouse: Poseida: Research Funding; Seagen: Research Funding; Janssen: Research Funding; Bristol Meyer Squibb: Research Funding; Pfizer: Membership on an entity's Board of Directors or advisory committees, Research Funding. Pophali: Marker Therapeutics: Research Funding; Fate Therapeutics: Research Funding; SeaGen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding. Turtle: Novartis: Consultancy; Boxer Capital: Consultancy; ArsenalBio: Current holder of stock options in a privately-held company; Prescient Therapeutics: Consultancy; Cargo Therapeutics: Current holder of stock options in a privately-held company, Membership on an entity's Board of Directors or advisory committees; Eureka Therapeutics: Current holder of stock options in a privately-held company; Myeloid Therapeutics: Current holder of stock options in a privately-held company; IGM Biosciences: Consultancy; T-CURX: Membership on an entity's Board of Directors or advisory committees; Advesya: Membership on an entity's Board of Directors or advisory committees; eGlint: Current holder of stock options in a privately-held company, Membership on an entity's Board of Directors or advisory committees; Caribou Biosciences: Current holder of stock options in a privately-held company, Membership on an entity's Board of Directors or advisory committees; Nektar Therapeutics: Research Funding; Abbvie: Consultancy; Kyverna: Membership on an entity's Board of Directors or advisory committees; Myeloid Therapeutics: Membership on an entity's Board of Directors or advisory committees; ArsenalBio: Membership on an entity's Board of Directors or advisory committees; Century Therapeutics: Consultancy; Celgene, a BMS company: Membership on an entity's Board of Directors or advisory committees; Differentia Bio: Membership on an entity's Board of Directors or advisory committees; Juno Therapuetics, a BMS company: Research Funding. Phillips: Novartis: Membership on an entity's Board of Directors or advisory committees. Pasquini: Janssen: Research Funding; Novartis: Research Funding; Bristol Myers Squibb: Consultancy, Research Funding; Kite, a Gilead Company: Honoraria, Research Funding. Ahmed: Janssen: Research Funding; Bristol Myers Squibb: Research Funding; Merck: Research Funding; Nektar: Research Funding; Kite, a Gilead Company: Consultancy, Research Funding; Xencor: Research Funding; Myeloid Therapeutics: Consultancy; ADC Therapeutics: Consultancy. Ganguly: Kite Pharma: Consultancy, Honoraria; BMS: Consultancy, Honoraria; Sanofi Genzyme: Consultancy, Honoraria; AstraZeneca: Consultancy, Honoraria.